BiliaryTractCancer near Astoria, NY

Biography: Rohit K. Jain MD, MPH is an Associate Professor of Medicine at Weill Cornell Medicine and Attending Physician at NewYork-Presbyterian Hospital- Weill Cornell Medical Center. Dr. Jain earned his medical degree at Topiwala National Medical College and B.Y.L. Nair Charitable Hospital, Mumbai, India. He completed Internal Medicine Residency at Johns Hopkins University/Sinai Hospital of Baltimore and Hematology-Oncology Fellowship at Roswell Park Cancer Institute University at Buffalo, New York. After fellowship, Dr. Jain, joined the H. Lee Moffitt Cancer Center in Tampa, Florida as Assistant Professor, and was instrumental in building the bladder cancer program. Dr. Jain was selected as Castle Connolly "Top Doctor" for 2024, as well as one of America's Best Prostate Cancer Oncologist by Newsweek magazine in 2024. Dr. Jain was recruited to Weill Cornell Medicine (WCM) in 2024. He cares for patients with bladder (urothelial), kidney (renal), prostate and testicular cancers, with a major focus in urothelial cancers. His research interests are primarily in urothelial and prostate cancers. Dr. Jain is involved in biomarker research as well as developing innovative clinical trials for patients, and he has received funding from the National Cancer Institute (NCI).

Biography: Dr. Charles Shapiro, MD is a Hematology Specialist who practices in New York, NY. He is 68 years old and has been practicing for 41 years. Dr. Charles Shapiro, MD is affiliated with Mount Sinai Hospital.

Biography: Benjamin Samstein, MD is Chief of Liver Transplantation and Hepatobiliary Surgery in the Department of Surgery at NewYork-Presbyterian/Weill Cornell Medicine and Associate Professor of Surgery at Weill Cornell Medical College, Cornell University. Dr. Samstein is the Surgical Director of the Living Donor Liver Transplant Program at NYP. Dr. Samstein is a renowned pioneer in minimally invasive liver surgery and state-of-the-art laparoscopic techniques for liver cancer. Dr. Samstein is a Castle Connolly Top Doctor. Dr. Samstein heads up the multidisciplinary liver transplantation and hepatobiliary surgery team at NYP/Weill Cornell. His specialties include the most advanced laparoscopic procedures for liver cancer, benign liver tumors and hepatobiliary pancreatic disease. He has been invited to talk about minimally invasive liver surgery throughout the world. He is a member of many surgical societies including a founding member of the International Laparoscopic Liver Society (ILLS), American Society of Transplant Surgery, American Hepato-Pancreato-Biliary Association (AHPBA). He is the Chair of the Medical Advisory Board of LiveOnNY and served as the Regional representation to the Liver and Intestine Committee of UNOS from 2014 to 2016. Dr. Samstein is well-published in the field, authoring more than 40 peer-reviewed articles in prestigious medical and surgical journals, books and book chapters. Other areas of clinical expertise include hepatic adenoma, hepatic hemangioma, cholangiocarcinoma, colorectal metastasis, live donor nephrectomy, laparoscopic living donor nephrectomy, and pediatric liver and organ transplant. Dr. Samstein received his undergraduate degree from Cornell University in 1992 and earned his MD at the State University of New York at Stonybrook in 1997. He did his internship and residency in general surgery at NYP/Columbia, and completed a research fellowship at the Mayo Clinic in 2001. He completed a fellowship in ASTS Multi-organ transplant at NYP/Columbia in 2006. He was Assistant Professor of Surgery at Columbia University Medical Center from 2006 to 2015. He served as Program Director of the transplant surgery fellowship at Columbia University from 2007 to 2015. He is a reviewer for American Journal of Transplantation, Transplantation, Liver Transplantation, Pediatric Transplantation, Clinical Transplantation among other journals. List of Publications by Dr. Samstein PubMed

Biography: Dr. Ingham is Assistant Professor of Medicine in the Division of Hematology and Oncology at New York Presbyterian Hospital/Columbia University Medical Center. He received his medical degree from the University of Massachusetts Medical School and completed internship and residency training in Internal Medicine at New York University Medical Center, where he served as Chief Resident. He then completed fellowship training in Hematology and Medical Oncology at New York Presbyterian Hospital/Columbia University Medical Center where he served as Chief Fellow. Dr. Ingham specializes in the care of patients with sarcoma and gastrointestinal cancers and is also an active member of the experimental therapeutics unit. His research focuses on the development and clinical evaluation of new treatments for patients with sarcoma. He leads a National Cancer Institute (NCI) sponsored clinical trial evaluating a new treatment approach for uterine leiomyosarcoma based on research conducted at Columbia University. He also leads several other investigator-initiated clinical trials evaluating new targeted and immunotherapy based treatment approaches for leiomyosarcoma, liposarcoma and other types of sarcoma. He is the author of two recent authoritative reviews on the treatment of sarcoma published in the Journal of Clinical Oncology. He is the recipient of the 2019 Conquer Cancer Foundation of ASCO Career Development Award from the Sarcoma Foundation of America in recognition of his research and was also named a 2019 NextGen Innovator by HemOnc Today, among other awards and honors. His overall goal is to provide patients with compassionate oncologic care and access to the most promising treatment approaches.

Biography: Dr. Fojo received his MD and PhD from the University of Miami and completed internal medicine training at Washington University School of Medicine / Barnes Hospital. He joined the National Cancer Institute in 1982 as a Clinical Associate in the Medicine Branch and after training with Drs. Ira Pastan and Michael Gottesman, became a Principal Investigator in the Medicine Branch of the National Cancer Institute. As a Principal Investigator he went on to establish a highly successful translational clinical program that began by exploring agents to reverse drug resistance, continued with work on the optimal use of Taxol®, and the development of novel microtubule-targeting agents and has focused on the development of therapies for endocrine and neuroendocrine cancers. Dr. Fojo has expertise in the management of patients with adrenocortical cancer, malignant pheochromocytoma and other neuroendocrine malignancies, and thyroid cancer. These cancers also comprise areas of very active basic science interest given their unique properties and the possibilities to target such cancers more precisely. The ultimate goal is to develop novel therapies for these often very refractory cancers so that there will be additional options available for treatment for patients with these cancers. Ongoing laboratory efforts are focused on developing such novel therapies to treat patients with adrenal cancer, pheochromocytoma and a spectrum of neuroendocrine tumors. In the laboratory Dr. Fojo has also worked to understand the molecular basis of drug resistance, and was involved in the original work relating to several ABC transporters. Additionally, his laboratory originally identified rearrangements involving the MDR-1 gene as a novel mechanism of drug resistance in several cancers, a molecular event recently demonstrated as very important in ovarian cancer. He has also been very involved in research on microtubule-targeting agents, helping to establish as a novel paradigm the interference with microtubule trafficking, rather than mitosis, for the mechanism of action for these important drugs. In addition to his clinical expertise Dr. Fojo has been very interested in the design, conduct and interpretation of oncology clinical trials and in collaboration with Wilfred Stein, PhD and Susan Bates, MD has helped to pioneer a novel method of analysis that dissects rates of tumor growth and regression as concurrent events. Related to this he has also written extensively about the cost of cancer therapeutics, the magnitude of the problem and how this might be addressed. Dr. Fojo served as Program Director for the Medical Oncology Fellowship Program at the National Cancer Institute, the largest fellowship program in the NIH and one of the largest medical oncology programs in the United States. Over the years Dr. Fojo has helped to train more than 350 medical oncologists.